Valuation : ChitogenX Inc.

Market Cap 831K 601K 517K 486K 444K 56.73M 834K 5.75M 2.23M 29.11M 2.26M 2.21M 93.77M P/E 2023
-2.01x
P/E 2024 -3.99x
Enterprise Value 4.67M 3.38M 2.91M 2.73M 2.5M 319M 4.68M 32.3M 12.53M 164M 12.68M 12.4M 527M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
100%
Yield 2023 *
-
Yield 2024 -
3 years 0
Extreme 0
0.14
5 years 0
Extreme 0
0.6
10 years 0
Extreme 0
1
Manager TitleAgeSince
Chief Executive Officer 65 2024-02-27
Director of Finance/CFO 62 2018-09-17
Chief Tech/Sci/R&D Officer 68 -
Director TitleAgeSince
Chairman 67 2019-03-05
Chairman 65 2016-07-25
Chairman 65 -
Date Insider Type Main position Quantity % Market Cap. Importance
11/19/24 Buy

Chief Financial Officer

710,000 0.8541%
7/17/24 Option

Chief Executive Officer

544,400 0.6549%
7/17/24 Option

General Counsel

100,000 0.1203%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-96.00% 301K
-2.54%-3.60%-0.60%+15.17% 50.35B
-0.40%-5.03%+428.09%+499.20% 45.2B
-1.42%+2.05%+45.04%+19.36% 44.71B
-1.22%-3.82%+6.54%+71.48% 41.24B
+0.53%-1.67%+15.16%+49.88% 33.08B
-0.21%+8.50% - - 17.81B
-0.35%-3.32%+22.87%+116.19% 16.56B
-1.01%-0.38%+15.69%+28.39% 14.82B
-1.65%-2.67%+77.72%+37.63% 14B
Average -1.03%+0.01%+67.84%+82.37% 27.78B
Weighted average by Cap. -1.38%-0.46%+91.57%+121.80%

Financials

2023 2024
Net sales - -
Net income -6.23M -4.5M -3.87M -3.65M -3.33M -425M -6.25M -43.08M -16.72M -218M -16.91M -16.54M -703M -1.55M -1.12M -967K -909K -831K -106M -1.56M -10.75M -4.17M -54.41M -4.22M -4.13M -175M
Net Debt 6.21M 4.49M 3.86M 3.63M 3.32M 424M 6.22M 42.91M 16.65M 217M 16.84M 16.48M 700M 3.84M 2.78M 2.39M 2.25M 2.05M 262M 3.85M 26.55M 10.3M 134M 10.42M 10.19M 433M
Logo ChitogenX Inc.
ChitogenX Inc. is a Canada-based clinical-stage regenerative medicine company. The Company is engaged in the development of therapeutic tissue repair technologies to improve tissue healing. The Company is committed to the clinical development of its proprietary RESTORE technology platform, a muco-adhesive CHITOSAN based biopolymer matrix, specifically designed to deliver biologics such as platelet-rich plasma (PRP) or bone marrow aspirate concentrate (BMAC), to enhance healing in various musculoskeletal conditions. Ortho-R, its lead Chitosan-PRP hybrid biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports related injuries to tendons, ligaments, and cartilage such as the meniscus. Its other formulations are being developed to leverage the technology's performance characteristics, such as tissue adhesion, pliability, and ability to deliver biologics or therapeutics to various tissues damaged by trauma or disease.
Employees
-

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CHGX Stock